Prof Xavier Leleu speaks to ecancer about new approaches in transplant-ineligible NDMM.

In 2017, a new quadruple regimen was introduced for transplant-eligible patients, later found safe for those ineligible as well.

A phase three trial with 230 patients focused on an 18-month induction treatment using Bortezomib.

Results showed a significant improvement in MD negativity rates, highlighting the regimen's unexpected efficacy and synergy among the drugs.

The combination therapy managed side effects effectively, leading to its rapid adoption as the new standard of care.